PharmaEngine, Sentinel Oncology partner to advance SOL-578 Chk1 inhibitor

PharmaEngine has signed a collaboration and license deal with UK-based Sentinel Oncology for advancing the new drug development of SOL-578, a checkpoint kinase 1 inhibitor ... Read More